In addition, genetic alterations in PPP2CA (protein phosphatase 2 catalytic subunit alpha) that encodes the negative AKT regulator PP2A have also been observed in prostate cancer [42,43,44,45,46], and PP2A loss has been linked to prostate cancer progression and metastatic potential in the clinic [140]. Here, PTPA is linked to prostate cancer.